

February 23, 2024 | Issue 310

Editor's note

This note is produced every Friday by <u>KPMG</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe</u> to our <u>mailing</u> list here.

We welcome your feedback. Let us know if KPMG can help. Please reply to this email with any comments or requests.

> Subscribe here



Healthcare regulatory news

CMS released a <u>final rule</u> recalculating disproportionate share hospital (DSH) payments, allowing reimbursements only for services provided to beneficiaries for whom Medicaid is their primary insurer; an \$8B reduction in DSH payments is anticipated from 2024-2027.

The FDA granted accelerated approval for CAR-T immunotherapy, Amtagvi, the first cancer cell therapy for solid tumors; CAR-T immunotherapies have demonstrated success against certain blood cancers, but have had limited clinical efficiency with solid tumors, which account for 90% of all cancer types.

The Advanced Research Projects Agency for Health (ARPA-H) announced \$100M in funding for women's health research and development.

A progress report by CMS on No Surprises Act (NSA) arbitration between January-June 2023 shows 80% of payment disputes for out-of-network services were settled above the median in-network rate... A FAIR Health study found in-network care increased 2.3% across all specialties upon NSA implementation (Q4 2021- Q1 2022).

SAMHSA <u>announced</u> \$5M for LGBTQIA+ youth counseling, support programs, and tailored provider training.





Healthcare law and policy news

Novovax reached a \$475M settlement with Gavi, a public-private partnership with the WHO, for a 2021 advance purchase agreement (APA) for its COVID-19 vaccine prototype.

The Department of Justice (DOJ) is <u>investigating</u> Community Health Systems' (CHS) billing practices for potential False Claims Act violations; CHS <u>previously settled</u> with the DOJ for \$262M in 2018 for overbilling allegations.

A new <u>investigation</u> of Colorado-based UCHealth found 15,000+ lawsuits have been filed against patients on the insurers' behalf between 2019-2023; the investigation <u>alleges UCHealth used third-party collection</u> <u>agencies</u> to deliberately obfuscate their involvement.

MA beneficiaries are more likely to experience care delays in getting care due to prior approval requirements than traditional Medicare (22% vs 13%) per a new Commonwealth Fund study.

A Small Business Majority <u>poll of small business</u> found that nearly 25% of respondents stopped providing health coverage to their employees in response to rising healthcare costs.

Nearly 40% of Americans personally know someone who has died over an overdose and almost 13% have experienced the loss of a close friend or relative to overdose, according to an American Journal of Public Health study.

A Center for Connected Medicine (CCM)/KLAS Research <u>provider poll</u> found only 16% of respondents have systemwide Al governance policies.





Questions or comments, please send to <u>us-hclspractice@kpmg.com</u>.

kpmg.com/socialmedia











Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2024 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. USCS011380-1B

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.